Results 21 to 30 of about 400,342 (335)
Emerging immunotherapy for HCC: A guide for hepatologists
Hepatology, 2022 HCC is one of the most common cancers worldwide, and the third leading cause of cancer‐related death globally. HCC comprises nearly 90% of all cases of primary liver cancer.
F. Foerster +3 more
semanticscholar +1 more source
Hypoxia‐driven immunosuppression by Treg and type‐2 conventional dendritic cells in HCC
Hepatology, 2022 Hypoxia is one of the central players in shaping the immune context of the tumor microenvironment (TME). However, the complex interplay between immune cell infiltrates within the hypoxic TME of HCC remains to be elucidated.
Sheena Suthen +29 more
semanticscholar +1 more source
Risk factors for HCC in contemporary cohorts of patients with cirrhosis
Hepatology, 2022 Background and Aims: Etiological risk factors for cirrhosis have changed in the last decade. It remains unclear to what extent these trends in cirrhosis risk factors have changed HCC risk.
F. Kanwal +12 more
semanticscholar +1 more source
Therapeutic efficacy of FASN inhibition in preclinical models of HCC
Hepatology, 2022 Aberrant activation of fatty acid synthase (FASN) is a major metabolic event during the development of HCC. We evaluated the therapeutic efficacy of TVB3664, a FASN inhibitor, either alone or in combination, for HCC treatment.
Haichuan Wang +13 more
semanticscholar +1 more source
GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis
Hepatology, 2021 Most patients with HCC are diagnosed at a late stage, highlighting the need for more accurate surveillance tests. Although biomarkers for HCC early detection have promising data in Phase 2 case–control studies, evaluation in cohort studies is critical ...
A. Singal +8 more
semanticscholar +1 more source
Cell Death and Disease, 2021 Metabolic reprogramming is a new hallmark of cancer but it remains poorly defined in hepatocellular carcinogenesis (HCC). The fatty acid receptor CD36 is associated with both lipid and glucose metabolism in the liver.
Xiaoqing Luo +11 more
semanticscholar +1 more source
Hepatology, 2022 Background and Aims: The sensitivity of current surveillance methods for detecting early‐stage hepatocellular carcinoma (HCC) is suboptimal. Extracellular vesicles (EVs) are promising circulating biomarkers for early cancer detection.
Na Sun +53 more
semanticscholar +1 more source
Diabetes medications and risk of HCC
Hepatology, 2022 Type 2 diabetes mellitus is a recognized risk factor for HCC in patients with liver disease, independent from the etiology of their liver disease. Hence, prevention and treatment of type 2 diabetes mellitus and its underlying cause, insulin resistance ...
M. C. Plaz Torres +5 more
semanticscholar +1 more source
Intratumor heterogeneity in HCC
Aging, 2015 Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related death worldwide [1], generally arising on the background of chronic liver diseases such as chronic viral hepatitis, alcohol-induced liver injury, or fatty liver disease. So far, classification proposals for HCC based on molecular markers are not yet routinely applied in ...
Friemel, Juliane +2 more
openaire +5 more sources
A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma. [PDF]
, 2015 Hepatocellular carcinoma (HCC), the second leading cause of cancer deaths worldwide, is difficult to treat and highly lethal. Since HCC is predominantly diagnosed in patients with cirrhosis, treatment planning must consider both the severity of liver ...
Busuttil, Ronald W +2 more
core +2 more sources